Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Mitsuru WatanabeYuri NakamuraZuzanna MichalakNoriko IsobeChristian BarroDavid LeppertTakuya MatsushitaFumie HayashiRyo YamasakiJens KuhleJun-Ichi KiraPublished in: Neurology (2019)
sGFAP and sNfL are likely to be good biomarkers of disease activity and disability, and the sGFAP/sNfL quotient at relapse is a potential diagnostic marker for NMOSD.